Jianjian Peng

This inventor holds 9 USPTO granted patents and 4 published patent applications and 5 EPO patents. Top assignees: Dingfu Biotarget Co., Ltd., Shihuida Pharmaceutical Group (Jilin) Co., Ltd.. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jianjian Peng. Retrieved from https://idiyas.com/inventor/jianjian-peng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 8(Granted Patents)

Location History:

Suzhou, CN (2022)
Jiangsu, CN (2019 - 2024)

Company Filing History:

8 out of 9

Dingfu Biotarget Co., Ltd.

patents

1 out of 1

Shihuida Pharmaceutical Group (Jilin) Co., Ltd.

patent

Years Active: 2019-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252542 - Anti-CD137 antibodies and method of treating colorectal cancer using them (2025-03-18),

2. 11987609 - Proteinaceous heterodimer and use thereof (2024-05-21),

3. 11845806 - Proteinaceous heterodimer and use thereof (2023-12-19),

4. 11795230 - Anti-CD27 antibodies and use thereof (2023-10-24),

5. 11529425 - Immunoconjugates comprising signal regulatory protein alpha (2022-12-20),

6. 11357826 - IL-10 EGFR antibody fusion protein and uses thereof (2022-06-14),

7. 10875926 - Fully human antibody against human CD 137 (2020-12-29),

8. 10624974 - Anti-OX40 antibody and application thereof (2020-04-21),

9. 10471124 - Proteinaceous heterodimer and use thereof (2019-11-12),

Title: Innovations and Contributions of Inventor Jianjian Peng

Introduction

Jianjian Peng is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of nine patents to his name, his work has the potential to impact cancer treatment and other medical applications.

Latest Patents

Among his latest patents is the development of Anti-CD137 antibodies and methods for treating colorectal cancer using these antibodies. This invention involves an antibody that can specifically bind to CD137 or an antigen-binding fragment thereof. The antibody may include a light chain variable region and a heavy chain variable region with one or more mutations. This innovation aims to prepare a drug that can effectively target CD137, which is crucial in cancer therapy. Another significant patent involves proteinaceous heterodimers, which includes pharmaceutical compositions, medicaments, and kits that utilize these heterodimers. These patents reflect his commitment to advancing medical science through innovative solutions.

Career Highlights

Jianjian Peng has worked with several prominent companies in the biotechnology sector. Notably, he has been associated with Dingfu Biotarget Co., Ltd. and Shihuida Pharmaceutical Group (Jilin) Co., Ltd. His experience in these organizations has contributed to his expertise in developing cutting-edge medical technologies.

Collaborations

Throughout his career, Jianjian has collaborated with talented individuals in the field. Some of his notable coworkers include Ting Xu and Yan Luan. These collaborations have likely enriched his research and development efforts, leading to innovative breakthroughs.

Conclusion

Jianjian Peng's contributions to biotechnology, particularly in the area of therapeutic antibodies, showcase his innovative spirit and dedication to improving healthcare. His patents and collaborations highlight the importance of teamwork in advancing scientific research.

Profile summary based on public USPTO records.